TORONTO, ONTARIO--(Marketwired - May 27, 2016) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a
summary of its financial results for the three months ending March 31, 2016. Key highlights include:
- First quarter (Q1) 2016 Net Revenues of $3,772,463 increased by 14% versus Q1 2015
- Q1 2016 Pharmaceutical Net Revenues of $3,546,608 increased by 10% overall versus Q1 2015, with Canadian Pharmaceutical Net
Revenues increasing by 6% and International Pharmaceutical Net Revenues more than doubling versus Q1 2015
- Q1 2016 EBITDA1 of $1,262,854 decreased by 4% versus Q1 2015
- Q1 2016 Net Income After Tax ("NIAT") of $951,854 decreased by 1% versus Q1 2015
- The Company maintained a NIAT margin of 25% for Q1 2016, consistent with the average NIAT margin for the 2013, 2014, and
2015 fiscal years
- Q1 2016 Fully Diluted EPS was $0.07 as compared to $0.07 in Q1 2015
- Trailing Twelve Months Fully Diluted EPS was $0.26 for the twelve months ended March 31, 2016 as compared to $0.25 for the
twelve months ended March 31, 2015
- The Company remains free of long-term debt and has an unutilized operating line of credit
- As at March 31, 2016, the Company had cash, cash equivalents and short term investments totalling $9,262,124, as compared
to $9,715,476 as at December 31, 2015 - a 5% decrease
- Working capital, which is the difference between current assets and current liabilities, increased by 8% from $10,821,785
as at December 31, 2015 to $11,717,895 as at March 31, 2016
- Total Shareholders' Equity increased by 8% from $12,151,482 at December 31, 2015 to $13,148,836 at March 31, 2016
- Trailing Twelve Months Return on Equity to March 31, 2016 was 34%
"Q1 2016 marked BioSyent's 23rd consecutive profitable quarter," commented René Goehrum, President and CEO of
BioSyent. "We continued to strengthen our product portfolio during the quarter, making progress in the commercialization of the
CYSVIEW® product in Canada used with blue light cystoscopy and successfully re-launching our urgent care product,
Atropine, for use in Aguettant System® pre-filled syringes, to Canadian hospitals. In addition, with our
FeraMAX® brand recently being named the #1 Doctor and #1 Pharmacist recommended over-the-counter iron supplement in
Canada (Rogers Healthcare Group national survey of 820 physicians and 2,321 pharmacists), we expect further momentum in
the pharmaceutical business. Our Q1 2016 Revenue, EBITDA and NIAT results are in line with our plan and reflect our enhanced
investment in human capital which primarily occurred last year. With products such as CYSVIEW® and Augettant
System® Atropine and Phenylephrine in the early stages of commercialization, and growth in our international business,
we expect continued revenue growth through the balance of 2016."
Mr. Goehrum continued, "Our recent signing of an exclusive Distribution Agreement for two new cardiovascular products in
Canada with estimated annual peak penetration revenues of $20 million and our establishment of an international subsidiary will
support further long-term profitable growth both in Canada and internationally."
The CEO presentation on the Q1 2016 Results is available at the following link: www.biosyent.com/q1-16/
The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion & Analysis for the
three months ended March 31, 2016 and 2015 will be posted on www.sedar.com on
May 27, 2016.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty
pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully
developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the
healthcare professionals that treat these patients by marketing its products through its community, hospital and international
business units.
As of the date of this press release, the Company has 14,026,087 shares issued and outstanding.
| BioSyent Inc. |
| Interim Unaudited Consolidated Statements of Comprehensive Income |
| |
|
|
|
|
|
|
| In Canadian Dollars |
|
Q1 2016 |
|
Q1 2015 |
|
% Change |
| Net Revenues |
|
3,772,463 |
|
3,306,100 |
|
14% |
| Cost Of Goods Sold |
|
717,102 |
|
708,735 |
|
1% |
| Gross Profit |
|
3,055,361 |
|
2,597,365 |
|
18% |
| Operating Expenses |
|
1,751,451 |
|
1,277,432 |
|
37% |
| Net Income Before Tax |
|
1,303,910 |
|
1,319,933 |
|
-1% |
| Tax (including Deferred Tax) |
|
352,056 |
|
357,221 |
|
-1% |
| Net Income After Tax |
|
951,854 |
|
962,712 |
|
-1% |
| Net Income After Tax % to Net Revenues |
|
25% |
|
29% |
|
|
| EBITDA1 |
|
1,262,854 |
|
1,314,324 |
|
-4% |
| EBITDA % to Net Revenues |
|
33% |
|
40% |
|
|
- EBITDA - is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning
under International Financial Reporting Standards ("IFRS") and therefore may not be comparable to similar measures
presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes,
depreciation and amortization.
| BioSyent Inc. |
| Interim Unaudited Consolidated Statements of Financial Position |
| |
|
|
|
|
|
|
| AS AT |
|
March 31, 2016 |
|
December 31, 2015 |
|
% Change |
| ASSETS |
|
|
|
|
|
|
| Trade receivables |
|
$ 1,798,531 |
|
$ 1,341,668 |
|
34% |
| Other receivables |
|
43,596 |
|
43,610 |
|
0% |
| Inventory |
|
1,793,807 |
|
1,744,936 |
|
3% |
| Prepaid expenses and deposits |
|
219,209 |
|
297,791 |
|
-26% |
| Derivative assets |
|
11,422 |
|
34,569 |
|
-67% |
| Short term investments |
|
7,187,837 |
|
5,322,859 |
|
35% |
| Cash and cash equivalents |
|
2,074,287 |
|
4,392,617 |
|
-53% |
| Current Assets |
|
13,128,689 |
|
13,178,050 |
|
0% |
| |
|
|
|
|
|
|
| Equipment |
|
251,521 |
|
230,255 |
|
9% |
| Intangible assets |
|
1,159,466 |
|
1,079,488 |
|
7% |
| Deferred tax asset |
|
120,208 |
|
120,208 |
|
0% |
| TOTAL NON CURRENT ASSETS |
|
1,531,195 |
|
1,429,951 |
|
7% |
| |
|
|
|
|
|
|
| TOTAL ASSETS |
|
$ 14,659,884 |
|
$ 14,608,001 |
|
0% |
| LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
| Current liabilities |
|
$ 1,410,794 |
|
$ 2,356,265 |
|
-40% |
| Deferred tax liability |
|
100,254 |
|
100,254 |
|
0% |
| Total Equity |
|
13,148,836 |
|
12,151,482 |
|
8% |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
|
$ 14,659,884 |
|
$ 14,608,001 |
|
0% |
| |
|
|
|
|
|
|
This press release may contain information or statements that are forward-looking. The contents herein represent our
judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or statements. Potential risks may include, but are not limited
to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining
regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of
the same.